期刊
IMMUNOLOGY LETTERS
卷 223, 期 -, 页码 33-43出版社
ELSEVIER
DOI: 10.1016/j.imlet.2020.04.009
关键词
Hepatocellular carcinoma; NK cell; Patient-derived xenograft; Immunotherapy
类别
资金
- Natural Science Foundation of China [81788101, 31670908, 81972679]
- National Key R&D Program of China [2019YFA0508502]
- Ministry of Science & Technology of China [2017ZX10203206003, 2017ZX10202203-002-001]
- Chinese Academy of Science [XDB29030201]
- Fundamental Research Funds for the Central Universitie [WK2070000107]
Hepatocellular carcinoma (HCC) is a world-wide health problem. Poor and delayed diagnoses as well as high recurrence rate resulting in high mortality rate. In this study, we established a patient-derived xenograft (PDX) model from HCC patient, and continuously maintained with subcutaneous passage more than 20 times. This HCC PDX tumor exhibited the same histological characteristics with the HCC patient and could be used to verify therapeutic effect of liver cancer. We further evaluated this PDX model by experimental chemotherapy, demonstrating that this HCC PDX model was sensitive to sorafenib treatment. Further, the potential of natural killer cell-based immunotherapy for HCC was tested using this model. We found that NK92 cells effectively suppressed the tumor growth in vivo and prolonged the survival time of HCC-bearing PDX mice. This study indicates that HCC PDX model is a good platform to testify the efficacy of preclinical chemotherapy and immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据